Funding
Retroscreen Virology Ltd, a contract research organisation specialising in anti-viral research, has raised £2.6 million of equity funding from new investors led by Aquarius Equity Partners Ltd with IP Venture Fund.
In recent months, the company has experienced an increased demand for its services from the biotechnology and pharma industries. The new capital will allow Retroscreen to increase its capacity and develop new experimental challenge study models of pathogens, including enteric viruses such as norovirus.
Since its first round funding in 2006, Retroscreen has become the world’s leading centre for antiviral and vaccine-related research. It is the only contract research organisation to offer experimental infection studies with viruses in human volunteers under quarantine conditions (human challenge studies).
The company was founded in 1989 by John Oxford, Professor of Virology at the University of London.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
